Bliss GVS Pharma Limited unveiled a leadership refresh in its boardroom as the company’s July 3, 2026 board meeting approved a set of key moves. In a move aligned with governance strengthening, the board accepted the nomination and appointed Santosh Parab as an Additional Director in the capacity of Non-Executive, Non-Independent Director, effective July 3, 2026. At the same meeting, the company disclosed that Rahul Adakmol will take over as Chief Executive Officer from July 15, 2026, signaling a new chapter in Bliss GVS’s executive leadership. Simultaneously, Narsimha Shibroor Kamath has stepped aside from the CEO role with effect from the close of business on July 14, 2026, though he will continue to serve as Managing Director of the company. The announcements were delivered via video conferencing, underscoring the firm’s continuity-focused approach during a period of leadership transition.